The Patent Finder

Terms ending in 2037

2SEVENTY Bio, Inc.

Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,560,547Methods of Making T Cell Compositions
In force
 · Medium confidence
2SEVENTY Bio, Inc.In forceMedium confidence
US 12,760,099Multipartite Signaling Proteins and Uses Thereof
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 12,006,369Bcma Chimeric Antigen Receptors
In force
 · High confidence
2SEVENTY Bio, Inc.In forceHigh confidence
US 11,912,746PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 12,391,734PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
US 12,264,343TCRa HOMING ENDONUCLEASE VARIANTS
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
6 of 6 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited